Substance / Medication

Isradipine

Overview

Active Ingredient
isradipine
RxNorm CUI
33910
Labeler: AvKAREUpdated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Applications of isradipine in human addiction studies: A systematic literature review.
Natal Samantha, Young Cara C, Kaur Karamveer et al. · Exp Clin Psychopharmacol · 2023
PMID: 36595455Meta-AnalysisFull text (PMC)
Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial.
Young Cara C, Papini Santiago, Minami Haruka et al. · Neuropsychopharmacology · 2024
PMID: 38789642RCTFull text (PMC)
Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals.
Johnson Bankole A, Roache John D, Ait-Daoud Nassima et al. · Int J Neuropsychopharmacol · 2005
PMID: 15916717RCT
Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
[object Object] · Ann Intern Med · 2020
PMID: 32227247ObservationalFull text (PMC)
Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
Ramasahayam Bindu, Eedara Basanth Babu, Kandadi Prabhakar et al. · Drug Dev Ind Pharm · 2015
PMID: 24641324Observational
Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics.
Tirunagari Mamatha, Jangala Venkateswara Rao, Khagga Mukkanti et al. · Arch Pharm Res · 2010
PMID: 20661712Observational
Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study.
Park Jin-Hee, Park Yoo-Sin, Rhim Si-Youn et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2009
PMID: 19041284Observational
The dihydropyridine isradipine inhibits the murine but not the bovine A-wave response of the electroretinogram.
Banat Mohammed, Lüke Matthias, Siapich Siarhei A et al. · Acta Ophthalmol · 2008
PMID: 18752519Observational
Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
Widimský Jirí, Sirotiaková Jana · Curr Med Res Opin · 2006
PMID: 16834827Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Isradipine (substance)
SNOMED CT
386862002
UMLS CUI
C0071304
RxNorm CUI
33910
Labeler
AvKARE

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.